MA28747B1 - Dérivés de pyridine - Google Patents

Dérivés de pyridine

Info

Publication number
MA28747B1
MA28747B1 MA29626A MA29626A MA28747B1 MA 28747 B1 MA28747 B1 MA 28747B1 MA 29626 A MA29626 A MA 29626A MA 29626 A MA29626 A MA 29626A MA 28747 B1 MA28747 B1 MA 28747B1
Authority
MA
Morocco
Prior art keywords
pyridine derivatives
compounds
preparation
solvates
pain
Prior art date
Application number
MA29626A
Other languages
English (en)
Inventor
Charlotte Alice Louise Lane
Graham Nigel Maw
David James Rawson
Lisa Rosemary Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0416524A external-priority patent/GB0416524D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA28747B1 publication Critical patent/MA28747B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

"Dérivés de pyridine" La présente invention concerne des composés de formule (I) et leurs sels et produits de solvatation pharmaceutiquement acceptables, des procédés pour la préparation de, les intermédiaires utilisés dans la préparation de, et des compositions contenant ces composés et les utilisations de ces composés pour le traitement de la douleur.
MA29626A 2004-07-23 2007-01-23 Dérivés de pyridine MA28747B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0416524A GB0416524D0 (en) 2004-07-23 2004-07-23 Pyridine derivatives
US64607705P 2005-01-21 2005-01-21

Publications (1)

Publication Number Publication Date
MA28747B1 true MA28747B1 (fr) 2007-07-02

Family

ID=35786566

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29626A MA28747B1 (fr) 2004-07-23 2007-01-23 Dérivés de pyridine

Country Status (17)

Country Link
US (1) US7649004B2 (fr)
EP (1) EP1802580A2 (fr)
JP (1) JP4056081B1 (fr)
KR (1) KR20070026845A (fr)
AP (1) AP2007003887A0 (fr)
AU (1) AU2005266090A1 (fr)
BR (1) BRPI0513717A (fr)
CA (1) CA2574600C (fr)
CR (1) CR8859A (fr)
EA (1) EA200700099A1 (fr)
EC (1) ECSP077185A (fr)
IL (1) IL180430A0 (fr)
MA (1) MA28747B1 (fr)
MX (1) MX2007000885A (fr)
NO (1) NO20066055L (fr)
TN (1) TNSN07022A1 (fr)
WO (1) WO2006011050A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
WO2007083239A1 (fr) * 2006-01-23 2007-07-26 Pfizer Limited Dérivés de pyridine en tant que modulateurs du canal sodium
CN101675040A (zh) * 2007-05-03 2010-03-17 辉瑞有限公司 作为钠通道调节剂的2-吡啶甲酰胺衍生物
CA2685952C (fr) * 2007-05-03 2012-03-13 Pfizer Limited Derives de pyrazine
WO2011016234A1 (fr) 2009-08-04 2011-02-10 Raqualia Pharma Inc. Dérivés de picolinamide bloqueurs de ttx-s
WO2013021276A1 (fr) 2011-08-10 2013-02-14 Purdue Pharma L.P. Antagonistes du trpv1 comprenant un substituant dihydroxy et leurs utilisations
DK3239134T3 (da) 2013-01-31 2021-02-22 Vertex Pharma Pyridonamider som modulatorer af natriumkanaler
AU2014212426B8 (en) 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Quinoline and Quinoxaline Amides as Modulators of Sodium Channels
WO2014151472A1 (fr) * 2013-03-15 2014-09-25 Chromocell Corporation Modulateurs du canal sodique pour le traitement de la douleur
HUE037876T2 (hu) 2013-07-19 2018-09-28 Vertex Pharma Szulfonamidok mint nátriumcsatorna-modulátorok
MY181928A (en) 2013-09-10 2021-01-14 Chromocell Corp Sodium channel modulators for the treatment of pain and diabetes
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
EP3286178A1 (fr) 2015-04-21 2018-02-28 Almirall S.A. Dérivés hétérocycliques amino-substitués utilisés comme inhibiteurs des canaux sodiques
ES2927712T3 (es) 2017-05-16 2022-11-10 Vertex Pharma Amidas deuteradas de piridona y profármacos de las mismas como moduladores de canales de sodio
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
US20190343817A1 (en) 2018-02-12 2019-11-14 Vertex Pharmaceuticals Incorporated Method of treating pain
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US20230062053A1 (en) 2019-01-10 2023-03-02 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (fr) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Forme posologique comprenant un promédicament inhibiteur de canal sodique na 1,8
WO2020219867A1 (fr) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Compositions de co-cristaux d'amide de pyridone pour le traitement de la douleur
TW202128675A (zh) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
AU2022286511A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
CA3221938A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Analogues de tetrahydrofurane substitues utiles en tant que modulateurs de canaux sodiques
EP4347584A1 (fr) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Analogues de n-(hydroxyalkyl(hétéro)aryl)tétrahydrofurane carboxamide en tant que modulateurs de canaux sodiques
EP4346818A1 (fr) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Formes galéniques solides et schémas posologiques comprenant du (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl)tétrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
CA3221788A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Tetrahydrofuran-2-carboxamides substitues utiles en tant que modulateurs de canaux sodiques
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
WO2023205468A1 (fr) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Composés hétéroaryle pour le traitement de la douleur
WO2023205463A1 (fr) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Composés hétéroaryles pour le traitement de la douleur
WO2023205465A1 (fr) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Composés hétéroaryles pour le traitement de la douleur
WO2023205778A1 (fr) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Composés hétéroaryles pour le traitement de la douleur

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3332687A1 (de) 1983-09-10 1985-03-28 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2-amino-alkylpyridinen
JPS63179869A (ja) 1987-01-20 1988-07-23 Dainippon Pharmaceut Co Ltd ピペリジン誘導体
DE3933802A1 (de) 1989-10-10 1991-04-18 Basf Ag Pyridinderivate und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
CA2051705A1 (fr) 1990-06-19 1991-12-20 Kiyoaki Katano Derives de la pyridine, antagonistes de l'angiotensine ii
WO1996018616A1 (fr) 1994-12-12 1996-06-20 Merck & Co., Inc. 2-aminopyridines substituees utilisees comme inhibiteurs de synthase d'oxyde d'azote
WO1996018617A1 (fr) 1994-12-12 1996-06-20 Merck & Co., Inc. Pyridines 2-acylaminees substitutees utilisees comme inhibiteurs de synthase d'oxyde d'azote
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
JPH09132529A (ja) 1995-11-09 1997-05-20 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
CA2249607A1 (fr) 1996-04-03 1997-10-09 Neville J. Anthony Inhibiteurs de transferase de farnesyl-proteine
CA2249650A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
DE19831246A1 (de) 1998-07-11 2000-01-13 Clariant Gmbh Verfahren zur Herstellung von Arylpyridinen
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds

Also Published As

Publication number Publication date
IL180430A0 (en) 2007-06-03
KR20070026845A (ko) 2007-03-08
TNSN07022A1 (fr) 2008-06-02
AP2007003887A0 (en) 2007-02-28
EP1802580A2 (fr) 2007-07-04
WO2006011050A2 (fr) 2006-02-02
US7649004B2 (en) 2010-01-19
CR8859A (es) 2007-03-02
CA2574600A1 (fr) 2006-02-02
CA2574600C (fr) 2010-08-31
NO20066055L (no) 2007-01-24
MX2007000885A (es) 2007-03-12
ECSP077185A (es) 2007-02-28
WO2006011050A3 (fr) 2006-10-05
AU2005266090A1 (en) 2006-02-02
JP2008507503A (ja) 2008-03-13
US20080312235A1 (en) 2008-12-18
JP4056081B1 (ja) 2008-03-05
BRPI0513717A (pt) 2008-05-13
EA200700099A1 (ru) 2007-08-31

Similar Documents

Publication Publication Date Title
MA28747B1 (fr) Dérivés de pyridine
MA29926B1 (fr) Derives de pyrazine
TN2009000450A1 (fr) Derives de pyridine
MA31894B1 (fr) Composes organiques
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
TN2011000316A1 (fr) Derives de sulfonamides
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
TNSN08139A1 (fr) Composes therapeutiques
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA27775A1 (fr) Composes organiques
MA31754B1 (fr) Cis-imidazolines chirales
TN2009000138A1 (fr) Biaryl-ether-urees
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
MA31766B1 (fr) Composés organiques
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA27801A1 (fr) Nouveaux composes heterocycliques pour le traitement des affections inflammatoires et allergiques, leur procede de preparation et compositions pharmaceutiques les contenant
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale